

Award Number: W81XWH-15-1-0120

**TITLE:** Identification of androgen receptor-specific enhancer RNAs

**PRINCIPAL INVESTIGATOR:** Yin-Yuan Mo

**CONTRACTING ORGANIZATION:**

University of Mississippi Medical Center  
Jackson, MS 39216

**REPORT DATE:** August 2017

**TYPE OF REPORT:** Final

**PREPARED FOR:** U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

**DISTRIBUTION STATEMENT:** Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved  
OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

|  |                         |  |                          |  |
|--|-------------------------|--|--------------------------|--|
| 1. REPORT DATE<br>August 2017  | 2. REPORT TYPE<br>Final | 3. DATES COVERED<br>05/15/2015 to 05/14/2017 |                          |  |
| 4. TITLE AND SUBTITLE<br><b>Identification of androgen receptor-specific enhancer RNAs</b>   |                         | 5a. CONTRACT NUMBER                          |                          |  |
|  |                         | 5b. GRANT NUMBER<br>W81XWH-15-1-0120         |                          |  |
|  |                         | 5c. PROGRAM ELEMENT NUMBER                   |                          |  |
| 6. AUTHOR(S)<br>Yin-Yuan Mo<br><br>E-Mail: ymo@umc.edu   |                         | 5d. PROJECT NUMBER                           |                          |  |
|  |                         | 5e. TASK NUMBER                              |                          |  |
|  |                         | 5f. WORK UNIT NUMBER                         |                          |  |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br><br>University of Mississippi Medical Center<br>2500 State Street, G652<br>Jackson, MS 39216   |                         | 8. PERFORMING ORGANIZATION REPORT NUMBER     |                          |  |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012  |                         | 10. SPONSOR/MONITOR'S ACRONYM(S)             |                          |  |
|  |                         | 11. SPONSOR/MONITOR'S REPORT NUMBER(S)       |                          |  |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for Public Release; Distribution Unlimited   |                         |  |                          |  |
| 13. SUPPLEMENTARY NOTES  |                         |  |                          |  |
| 14. ABSTRACT<br>The major goal of this application is to determine whether prostate cancer cells express enhancer RNAs in response to androgen treatment such that these enhancer RNAs may serve as novel biomarkers for prostate cancer diagnosis and prognosis. There are two Tasks in this application. First, we will perform global run-on assay and deep sequencing to identify AR-specific enhancer RNAs. Second, we will validate them and then determine their functional significance. The success of this study may lead to novel clinical applications such as identification of biomarkers or therapeutic targets for prostate cancer, especially for castration resistant prostate cancer. |                         |  |                          |  |
| 15. SUBJECT TERMS<br>lncRNA, eRNA, biomarker   |                         |  |                          |  |
| 16. SECURITY CLASSIFICATION OF:<br><br>a. REPORT U      b. ABSTRACT U      c. THIS PAGE U  |                         | 17. LIMITATION OF ABSTRACT<br>UU             | 18. NUMBER OF PAGES<br>9 | 19a. NAME OF RESPONSIBLE PERSON<br>USAMRMC |
|  |                         |  |                          | 19b. TELEPHONE NUMBER (include area code)  |

## **Table of Contents**

|  | <u>Page</u> |
|--|-------------|
| <b>Introduction.....</b>                 | 1           |
| <b>Body.....</b>                         | 1           |
| <b>Key Research Accomplishments.....</b> | 5           |
| <b>Reportable Outcomes.....</b>          | 5           |
| <b>Conclusion.....</b>                   | 5           |
| <b>References.....</b>                   | N/a         |
| <b>Appendices.....</b>                   | N/a         |

We revised the report per reviewer's comments where they were highlighted in yellow.

## Introduction

The androgen receptor (AR) is a nuclear receptor transcription factor required for normal prostate development and prostate cancer pathogenesis. AR is a very important druggable target. For instance, androgen deprivation therapy (ADT) is a frontline treatment for advanced prostate cancer. However, despite initial response, patients become resistant to ADT due to castration resistance. Extensive studies have suggested that multiple factors contribute to castration resistance. We hypothesize that long non-coding RNAs (lncRNAs) is one of the important factors, especially those AR specific enhancer RNAs (eRNAs), contributing to castration resistance. In this application, we proposed to determine whether we can identify such AR specific eRNAs.

There are two major tasks for this project:

**Task 1. Perform global run-on assay and deep sequencing to identify AR-specific enhancer RNAs**

**Task 2. Validation and functional significance of AR specific eRNAs**

Both tasks were finished. Major findings are reported as follows.

## Body

**Profiling identified several potential eRNAs that are induced by androgen.**

As newly discovered molecules, eRNAs are poorly characterized. Little is known whether they are dysregulated in prostate cancer. Thus, our first step was to identify these new molecules by profiling and then characterize them. Results indicate that a number of eRNAs are upregulated in response to androgen treatment. Bioinformatics analysis further narrows down three interesting eRNAs and their sequences are shown below.

Statistical analysis was performed using the Student's t-test (two groups) or a one-way ANOVA followed by post hoc Tukey test (multiple groups). Differences with P values less than 0.05 are considered significant.

### **AR-eRNA-#1 (117 bp)**

caccattacacaggactgccttcaggaaggttctgtccactgaaaagggtacagctttctagagggcaatagg  
tgatttctattaaatatcaaagacacactccttgccctt

This eRNA is localized to chr14:24408289-24408405. Literature search indicates that it is homologous to AS1eRNA that may enhance another lncRNA called *DHRS4-AS1*

### **AR-eRNA-#2 (504 bp)**

```
>hg19_dna range=chr18:54746000-54746503
tggaaaaaacacctgcagacggcgtgccaggggcccccgcttgtgtg
cccagggtgaggccttaggaggaggcagcagtgggtgtcggggagggatt
caggcctcctggctgtccaggccttagccaaccataatggcgaaac
agagccgctatcctgacttccacatacaagcattagaatctcccttgt
acaaaggaagaccatatcccaaccatacatgtgcacttgcataatggct
gtgcttatcaagtgggagggacatccagccctgggtccccccggcttagc
catctgtatgtactaaggacactgtctcagagcctgcaaacatgccat
ccctgcaatacccatgagtcaactcacctctcagaggagccttctggc
aattctgttgaatgttcccccaaccctgtattccctacacactgcctgct
ttatctctatagctgtggtcacaattggacggactgtatatttact
tatt
```

Bioinformatics analysis mapped this sequence at the upstream of the potential promoter of Linc-RoR. Linc-RoR is known for its role in stem cell maintenance. Our lab has also demonstrated that Linc-RoR is a repressor for p53 in response to DNA damage. Furthermore, Linc-RoR increases Myc mRNA stability through interaction with hnRNP I and AUF1. Thus, identification of this potential eRNA that may regulate Linc-RoR will provide new insight into lncRNA

regulation in prostate cancer, further implying that Linc-RoR might be also controlled by androgen.

### **AR-eRNA-#3 (468 bp)**


```
>hg19_dna range=chr19:51354315-51354782
tgcctcccaacactgttcagccagagcctccaccctgtctgcaggaca
gtctcaacgttccaccattaaatacttcttctgtcacatcctgcttattt
atgcctaaccaggtaggtttccatcgactgtgtctggcagcactcc
actgccaaccccagaataaggcgcgtcaggatccgaaggggcatggc
tggggatcagaacttctgggttttagtgaggatgggtccacccttga
atttcaaaggaggaaggaggctggatgtgaaggaactggggaggaaagt
gtcagttccgaactcttaggtcaatgaggaggagactgtaagggtccca
gctcccgggtactgtggaaatggctaaatcataatcctcagg
aagaagggtgtggaaatcctgagggttagagttctggtatatttgtggct
taaggctttggccct
```

Bioinformatics analysis indicated that this sequence is homologous to KLK3e which is a known androgen inducible eRNA. Of interest, KLK3e has been shown to positively regulate Kallikrein-related peptidase 3 (KLK3), which codes for prostate-specific antigen (PSA); PSA is a well-known AR-regulated gene.

### **Characterization of AR-eRNA-#1 and**


#### **AR-eRNA-#2**

Since literature suggest that this eRNA may enhance DHRS4-AS1, we first focused on whether AR-eRNA-#1 can regulate DHRS4-AS1 and castration resistance. Another reason for choosing AR-eRNA-#1 is that this eRNA is relatively small and easy to clone. We cloned AR-eRNA-#1 in CMV promoter



**Fig. 1 AR-eRNA#1 regulates DHRS4-AS1 which is involved in AR splicing.** A, Ectopic expression of AR-eRNA#1 upregulates DHRS4-AS1. B, Over-expression of DHRS4-AS1 increases AR3 level, as detected by qRT-PCR. Total RNA was extracted 48 h after transfection in both cases. Values are means  $\pm$  SE. \*\*, p < 0.01.

driven expression vector, and then introduced into LNCaP cells. As shown in Fig.1A, AR-eRNA#1 promotes DHRS4-AS1 expression. More interestingly, DHRS4-AS1 affected AR splicing which has been implicated in castration resistance. For instance, overexpression of DHRS4-AS1 increases the AR3 level (Fig.1 B). It is well known that AR3 is a major AR splice variant that has been shown to be important to castration resistance. Therefore, to better




**Fig. 2 Further validation of DHRS4-AS1 as a regulator for AR3 expression.** A, Knockout of DHRS4-AS1 by CRISPR/Cas9. B, DHRS4-AS1 knockout suppresses AR3 mRNA level as determined by qRT-PCR. C, DHRS4-AS1 knockout suppresses AR3 protein level, as determined by Western blot. Values in A and B are means  $\pm$  SE. \*\*, p < 0.01.

(Fig. 2A). As expected, DHRS4-AS1 KO suppressed AR3 at mRNA level (Fig. 2B) and protein level (Fig. 2C).

We then determined the effect of DHRS4-AS1 on castration resistance by KO and rescue experiments.

Colony formation and MTT assays revealed that the

determine the role of AR-eRNA-regulation of DHRS4-AS1 in castration resistance, we knocked out DHRS4-AS1 by CRISPR/Cas9 technology in 22Rv1 cells, a well-known castration resistant cell line. We chose two clones (#16 and #38) for further characterization



**Fig. 3 DHRS4-AS1 promotes castration resistance.** DHRS4-AS1 KO suppresses cell growth, whereas re-expression of DHRS4-AS1 in the KO cells (KO#38) partially restores the cell number. The cells were grown in absence of androgen. A, Colony formation assay. B, MTT assay. Values in B are means  $\pm$  SE. \*\*, p < 0.01.

suppression of cell growth in the KO cells was partially rescued by re-expression of DHRS4-AS1 (Fig.3 A&B).

For AR-eRNA-#2, we did initial characterization. We found that it may regulate Linc-RoR expression, but further experiments are still needed to confirm this. Although we planned to characterize AR-eRNA-#3, we were not able to perform experiments due to time constraints.

### **Key Research Accomplishments**

- Profiling identified several AR regulated eRNAs
- AR-eRNA-#1 can regulate DHRS4-AS1 expression
- We generated DHRS4-AS1 KO by CRISPR/Cas9
- DHRS4-AS1 KO and rescue assays suggest that DHRS4-AS1 can promote castration resistance

### **Reportable Outcomes**

A manuscript entitled “AR-eRNA-#1 confers castration resistance by regulation of DHRS4-AS1” is in preparation.

### **Conclusion**

Together, these results suggest that there exist a group of AR-regulated eRNAs which may impact prostate tumorigenesis and castration resistance. Thus, further characterization of these eRNAs will provide a better understanding of AR-mediated gene regulation and castration

resistance, and it will also help design a better strategy for prostate cancer therapy. In addition, these AR eRNAs may serve as biomarkers in prostate cancer.